Clinical Trial

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
Protocol Amendment History 1 change
critical Trial completed 2026-07-28
Trial Details
NCT Number NCT06944717
Lead Sponsor Vaxart
Conditions Norovirus Infections
Enrollment 60 participants
Start Date 2025-03-03
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-04-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-27